<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">Despite these small studies suggesting the benefit of drugs acting on RAS pathway, there is some data, albeit scarce, from animal models and human studies that treatment with ACE inhibitors and ARB could causeup regulation of ACE2 [
 <xref rid="bib24" ref-type="bibr">24</xref>]. Ibuprofen and thiazolidinediones have also been shown to do the same [
 <xref rid="bib25" ref-type="bibr">25</xref>,
 <xref rid="bib26" ref-type="bibr">26</xref>]. Increased expression of ACE2 could theoretically increase the risk of infection with SARS CoV-2. This could be a concern in people with diabetes who are at already elevated risk of infections because of many other factors.However, there is no evidence to support this hypothesis currently. In a retrospective analysis of 112 COVID-19 hospitalised patients with cardiovascular disease in Wuhan, there was no significant difference in the proportion of ACEI/ARB medication between non-survivors and survivors [
 <xref rid="bib27" ref-type="bibr">27</xref>]. This issue will be discussed in detail in another article to be published in special issue shortly.
</p>
